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a b s t r a c t
Progression of coronary arteries after transcatheter aortic valve replacement is an important
issue. Coronary revascularization in these patients can be challenging because of potential
hindrance posed by the artiﬁcial valve structure in getting access to the coronary ostium.
This gets even more difﬁcult in chronic total occlusions (CTOs) that represent the most
complex subset of coronary lesions. We report the ﬁrst case of coronary CTO revasculariza-
tion in a patient who underwent TAVR a few months prior and discuss the complexities
involved in intervening such lesions.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.1. IntroductionMore than 50,000 transcatheter aortic valve replacement
(TAVR) procedures have been performed worldwide and the
numbers are expected to increase. There will be a need for
coronary revascularization after these procedures particularly
in the high- and intermediate-risk group of patients who
undergo TAVR. Coronary revascularization after TAVR is
challenging for a variety of reasons after implantation of
self-expanding or balloon expandable valves. Chronic total
occlusion (CTO) percutaneous coronary intervention (PCI)
represents the pinnacle of complexity in coronary interven-
tion. This case report describes the complexity and challenges
of CTO PCI following a Corevalve (Medtronic Inc, MN, USA)
implantation.* Corresponding author at: Banner University Medical Center, 1300 N. 1
fax: +1 602 839 7661.
E-mail address: ashish.pershad@bannerhealth.com (A. Pershad).
http://dx.doi.org/10.1016/j.ihj.2015.06.014
0019-4832/# 2015 Cardiological Society of India. Published by Elsevie2. Case summaryA 60-year-old male with a history of coronary artery disease,
hypertension, hyperlipidemia, and severe peripheral artery
disease was diagnosed with severe symptomatic aortic valve
stenosis after he presentedwith class IV heart failure. His LVEF
was 20%. His coronary angiograms demonstrated a CTO of the
proximal right coronary artery (RCA) (Fig. 1) with left to right
collaterals from the septal perforator branches of the left
anterior descending (LAD) artery to the posterior descending
artery (PDA) and 3rd Diagonal branches to the posterolateral
artery (PLA). His left coronary system was free of ﬂow limiting
disease. He also underwent abdominal aortography that
demonstrated an infra-renal aortic occlusion consistent with
Leriche's syndrome. Due to the presence of Rentrop grade 32th Street Suite 407 Phoenix, AZ 85006, USA. Tel.: +1 602 839 7393;
r B.V. All rights reserved.
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Fig. 1 – Bilateral injection demonstrating long RCA CTO with
non-ambiguous proximal cap and good landing zone for
reentry.
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Fig. 2 – Successful reentry to the true lumen with Stingray
catheter.
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Fig. 3 – Stingray wire across the lesion.
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revascularization of the RCA CTO was deferred prior to TAVR.
His symptoms and LV dysfunction were attributed to the
severe aortic valve stenosis.
Based on his STS score, he was deemed a high risk for
traditional surgical aortic valve replacement (SAVR) and under-
went TAVR successfully via direct aortic approachwith a 31mm
Corevalve (Medtronic Inc, MN, USA). He had an uncomplicated
hospital course of 7 days and was discharged home.
At 2-month outpatient follow-up, his dyspnea had im-
proved but hewas now complaining of Class II angina andwas
found to have an abnormal pharmacological stress test with
inferior wall ischemia and an ejection fraction of 35%. A
clinical decision was made to revascularize the CTO of the
right coronary artery.
Due to the presence of an infra-renal aortic occlusion, the
procedure was planned with the intent to use bilateral upper
extremity access. Contralateral access was obtained with a
90 cm 6Fr JL 4 from the left radial artery for retrograde
visualization of collaterals. An EBU (Medtronic, Inc., Minnea-
polis, MN) shape was unable to engage the left main as it was
caught on the stent frame of the Corevalve (Medtronic Inc, MN,
USA). Antegrade access was performed with a 7Fr JR 4 catheter
from the right brachial artery. It was felt by the operators that
the right radial artery was not large enough to accommodate a
7Fr sheath and there was no availability of sheathless guiding
catheters. There was difﬁculty in engaging the RCA ostium
with the JR 4 catheter. It continued to get caught on the struts
of the Corevalve (Medtronic Inc, MN, USA), and, hence it was
switched out for an AL-0.75 and then a MP-1 catheter. Both
these catheters had identical issues with inter-action with the
Corevalve (Medtronic Inc, MN, USA) prosthesis. Attempts were
even made to wire the RCA from the cusp of the RCA through
the struts of the Corevalve (Medtronic Inc, MN, USA) but wereunsuccessful. Finally, a LIMA catheter was successful in
engaging the RCA ostium but the orientation was non-coaxial.
A Corsair catheter (Asahi Intecc, Nagoya, Japan) was advanced
up to the proximal cap of the RCA CTO with the support of a
Whisperwire (Abbott Vascular, CA, USA). Antegrade dissection
with a Pilot 200 wire (Abbott Vascular, CA, USA) was
performed. The Stingray catheter (Boston Scientiﬁc, MA,
USA) was then advanced within the subintimal space to the
reentry zone and successful reentry to the true lumen was
achieved with a StingRay wire (Boston Scientiﬁc, MA, USA)
(Figs. 2 and 3). The Pilot 200 wire (Abbott Vascular, CA, USA)
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Fig. 4 – Final angiographic results with a TIMI III flow.
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Antegrade PCI was then performed with deployment of 3 drug
eluting stent (DES) (Fig. 4).
Once the procedure was complete, a TR (Terumo Medical,
Somerset NJ) bandwas placed to the left radial artery and right
brachial artery with successful hemostasis. There were no
post-procedural complications and the patientwas discharged
home the next day after overnight observation. His angina has
resolved and on follow-up echocardiography his ejection
fraction has normalized.
3. DiscussionManagement of CAD after TAVR especially in the intermedi-
ate- and high-risk subgroup of patients remains an ongoing
challenge. PCI can be challenging because of potential
hindrance posed by the valve struts in getting access to
coronary ostia. CTOs are the most complex subset of coronary
lesions that add another level of difﬁculty. CTOs typically
demand greater guide catheter support to be able to use
specialized wires, catheters, and techniques. Co-axial guide
catheter engagement of the coronaries is essential for CTO PCI.
A few cases of post-TAVR intervention of non CTO coronary
lesions using femoral artery access have been described1;
however, this case is the ﬁrst reported case of successful
revascularization of a CTO using the brachial/radial artery
approach in a patient after TAVR.
Coronary occlusion immediately after TAVR from leaﬂet
impingement contained rupture; calciﬁc plaque embolization
and ﬂow turbulence obstructing left main ﬂow have all been
described in the literature2 but issues associated with
cannulation of coronary arteries for managing stable CAD
months or years after TAVR have not been previously
described in the literature.It is paramount to understand the three-dimensional
geometry of transcatheter aortic valves as it relates to the
aortic root anatomy and commissural orientation of the
devices. It requires comprehension of how the valve after
deployment will relate to the coronary ostia. Currently there
are CT software programs in development that will allow
prediction of this sort of information but they are currently in
phases of validation.3
There are two types of commercially available biopros-
thetic valves used for TAVR: The Sapien XT valve (Edward
Lifesciences, CA, USA) and the Core valve (Medtronic, MN,
USA). The Sapien XT valve uses a bovine pericardial valve
mounted on a balloon expandable cobalt chromium frame.
The design and height of this valve allows the valve to be
implanted such that, the coronary ostia are above the valve
struts. As a result, the coronary guiding catheter used to
engage the coronaries does not have to negotiate the struts.
The Corevalve (Medtronic Inc, MN, USA), on the other hand,
consists of a self-expanding nitinol frame with a porcine
pericardial tissue valve. The frame of this valve system has a
diamond- or rhomboid-shaped open cell conﬁguration. The
outﬂow part of the frame is above the coronary sinuses, while
the inﬂow portion anchors in the subannular plane. The frame
of this valve intentionally crosses and covers both the
coronary ostia. To engage the coronary arteries the coronary
guiding catheter has to traverse the stent struts as was done in
this case and this can be very difﬁcult to reliably do. The
Portico (St. Jude Medical, MN Minnesota) and Evolut R version
of the Medtronic Corevalve (Medtronic Inc, MN, USA) are
second-generation devices with larger cells for supposed
easier access into the coronaries.
Prior to PCI, aortic root angiography may be useful to
evaluate the valve as well as to locate the position of the
coronary ostia. In spite of the open cell design, substantial
friction and interaction between the catheter and the stent
frame was encountered in this case. Although the orienta-
tion of the RCA ostium from the aorta was not unusual the
usual-sized JR 4 catheter had enormous challenges in
navigating the stent struts from the right radial approach.
Whether this might have been easier from the femoral
approach or the left radial approach or with use of dedicated
radial artery catheters is conjectural.4 A trial and error
approach of several catheters was attempted before ﬁnding
success with a LIMA catheter for the RCA. Engaging the left
main coronary artery with an EBU catheter was also not
feasible. Reverting back to a JL4 catheter enabled access to
the left main coronary artery.
The issue of coronary revascularization prior to TAVR is
understudied and controversial. A comprehensive review of
the available data and current literature suggests that all
obstructive coronary lesions do not need to be revascularized
prior to TAVR; however, PCI may be beneﬁcial only in severe
proximal stenotic lesions that puts a substantial area of
myocardium at ischemic risk.5 This may be even somewhat
less concerning with self-expanding Corevalve (Medtronic Inc,
MN, USA) as compared to balloon expandable Sapien XT valve
(Edward Lifesciences, CA, USA) because it obviates the need for
rapid ventricular pacing and thereby has comparatively lower
risk of inducing ischemia and hemodynamic instability owing
to non-revascularized coronary arteries.5 In this case, because
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 4 7 6 – 4 7 9 479of the presence of satisfactory left to right collaterals and
the use of Corevalve for TAVR, further assessment or
revascularization of RCA CTOwas not performed before TAVR.
4. ConclusionsThis case demonstrates that CTO PCI is feasible after TAVR but
brings with it unique challenges that have not previously been
encountered. Meticulous planning and understanding of the
prosthetic valve geometry, spatial conﬁguration, and its
relation to the coronary ostia are essential to the success of
this procedure. Future iterations of transcatheter valves and
CT-guided algorithms might allow tailoring of valve choice
to aortic root anatomy that would include coronary artery
orientations.
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